SARS-CoV-2 RBD of Spike protein, Y449H, E484K, N501Y – C.1.2 lineage – South Africa
Description of SARS-CoV-2 RBD of Spike protein, Y449H, E484K, N501Y – C.1.2 lineage – South Africa
General information on SARS-CoV-2 RBD of Spike protein, Y449H, E484K, N501Y – C.1.2 lineage – South Africa
A new variant of SARS-CoV-2 has recently attracted the attention of scientists in South Africa. Lineage C.1.2 was first detected in the Mpumalanga and Gauteng provinces in May 2021. It is distinct from other circulating variants of SARS-CoV-2 but genetically close to the Lambda variant, first described in Peru and designated variant of interest in mid-June 2021. However, the new variant carries different mutations and deletions, several within the spike protein and the receptor-binding domain (RBD). RBD-associated amino acid changes Y449H, E484K, and N501Y were found to be predominant in this new cluster of coronaviruses. The combination of E484K and N501Y has previously been reported in the Beta (South Africa), Gamma (Brazil), and Mu (Colombia) variants. Mutation E484K has been found to correlate with increased resistance to convalescent plasma therapy, hinting at an enhanced ability to escape the immune response. Additionally, mutation N501Y, extremely prevalent among other variants of the virus, is expected to increase SARS-CoV-2 transmissibility. In contrast, less is known about the amino acid change Y449H. However, researchers have hypothesized that it might impact resistance to neutralization activity or modify the process of furin cleavage, therefore altering the replicative fitness of the new lineage.
Besides RBD-associated mutations, the new lineage was reported to carry amino acid changed C136F, R190S, D215G, H655Y, N679K, and T859N, and deletions Y144del and L242-A243del within the spike protein. While the impact of these mutations on SARS-CoV-2 fitness and transmissibility is still unknown, it is important to remark that this variant stands out from others due to the concerning accumulation of several mutations with potential biological significance. For this reason, despite its still low abundance among other circulating strains in South Africa (about 5%), it is important to increase surveillance and determine the potential effects of these different spike-associated mutations.
|Product name||SARS-CoV-2 RBD of Spike protein, Y449H, E484K, N501Y – C.1.2 lineage – South Africa|
|Expression system||Eukaryotic expression|
|Delivery condition||Dry Ice|
|Storage condition||4°C for short term; -20°c or -80°C for long term|
|Host species||Mammalian cells|
|Fragment Type||Spike protein fragment|
|Note||For research use only. Not suitable for in vitro diagnostic and human use.|